Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 24, 2010

Drug Name Review Type Class Manufacturer
Bepreve New Drug Initial Review Ophthalmic - Allergic Conjunctivitis Ista
Vivitrol New Drug Initial Review Opioid Antagonist Alkermes
Colcrys New Drug Initial Review Anti-Gout URL
Sabril New Drug Initial Review Anticonvulsant Lundbeck
Twynsta New Drug Initial Review Antihypertensive Combination Boehringer Ingelheim
Apriso New Drug Initial Review Ulcerative Colitis Salix
Besivance New Drug Appeal Ophthalmic Fluoroquinolone Bausch & Lomb
Ranexa New Drug Appeal Anti-Anginal Giliead
Vimpat New Drug Appeal Anticonvulsant UCB
Lamictal XR New Drug Appeal Anticonvulsant GlaxoSmithKline
Ulesfia New Drug Appeal Pediculocide Shionogi
Zenpep New Drug Appeal Pancreatic Enzyme Eurand
Xibrom PDL Appeal Ophthalmic � Anti-Inflammatory Ista
Istalol PDL Appeal Ophthalmic � Glaucoma Agent Ista